Announcement

Certara Awarded NIH Contract for Toxicology Consulting Support

Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system…

CertaraJanuary 10, 2023

Publication

Pharmacokinetics and Bioequivalence of the Lubiprostone Capsule in Healthy Chinese Subject

Learn how dose‑proportional PK and fed‑state bioequivalence confirmed for lubiprostone using Phoenix WinNonlin.

CertaraJanuary 10, 2023

Video

If your drug is a CYP3A substrate, we have good news for you!

CertaraJanuary 9, 2023

Announcement

Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme

PRINCETON, N.J., January 9, 2023 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,…

CertaraJanuary 9, 2023

Publication

Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis

Find out how renal function and albumin drive MPA clearance; 1–4 h sampling best predicts…

CertaraJanuary 9, 2023

Press Release

Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation

Certara improves software capabilities by expanding into deep learning and data fabric PRINCETON, N.J.— January…

CertaraJanuary 4, 2023

White Paper

Drug interactions with therapeutic proteins, regulatory expectations and modeling and simulation approaches

CertaraJanuary 3, 2023

Publication

Population Pharmacokinetics and Dosing Regimen Optimization of Linezolid in Cerebrospinal Fluid and Plasma of Post-operative Neurosurgical Patients

Explore how highly variable CSF penetration; PopPK modelling supports renal‑ and inflammation‑adjusted dosing using Phoenix…

CertaraDecember 22, 2022

Blog

New FDA requirement to support labeling on DDIs in the pediatric population

The effects of drug-drug interactions (DDIs) could differ in the pediatric population compared to adults.…

CertaraDecember 21, 2022

Blog

The Phoenix workflow shortcuts every pharmacokineticist needs

Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform can revolutionize your pharmaceutical organization’s approach to PK/PD…

CertaraDecember 16, 2022

Certara Awarded NIH Contract for Toxicology Consulting Support

Pharmacokinetics and Bioequivalence of the Lubiprostone Capsule in Healthy Chinese Subject

If your drug is a CYP3A substrate, we have good news for you!

Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme

Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis

Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation

Drug interactions with therapeutic proteins, regulatory expectations and modeling and simulation approaches

Population Pharmacokinetics and Dosing Regimen Optimization of Linezolid in Cerebrospinal Fluid and Plasma of Post-operative Neurosurgical Patients

New FDA requirement to support labeling on DDIs in the pediatric population

The Phoenix workflow shortcuts every pharmacokineticist needs

Newsletter sign up

Quick links

Solutions

Contact